Article Summary
玉婷婷,王永鹏,李雪梅,佟 锐,屈 娜.卵巢癌患者血清HB-EGF、TK1、GDF15水平与临床病理特征和预后的关系[J].现代生物医学进展英文版,2022,(7):1286-1291.
卵巢癌患者血清HB-EGF、TK1、GDF15水平与临床病理特征和预后的关系
Relationship between the Levels of Serum HB-EGF, TK1, GDF15 and Clinicopathological Characteristics and Prognosis in Patients with Ovarian Cancer
Received:September 06, 2021  Revised:September 30, 2021
DOI:10.13241/j.cnki.pmb.2022.07.019
中文关键词: 卵巢癌  HB-EGF  TK1  GDF15  临床病理特征  预后
英文关键词: Ovarian cancer  HB-EGF  TK1  GDF15  Clinicopathological Characteristics  Prognosis
基金项目:辽宁省科技攻关项目(2010225032)
Author NameAffiliationE-mail
玉婷婷 辽宁省肿瘤医院/中国医科大学肿瘤医院妇科 辽宁 沈阳 110042 yutingting_19850220@126.com 
王永鹏 辽宁省肿瘤医院/中国医科大学肿瘤医院妇科 辽宁 沈阳 110042  
李雪梅 辽宁省肿瘤医院/中国医科大学肿瘤医院妇科 辽宁 沈阳 110042  
佟 锐 辽宁省肿瘤医院/中国医科大学肿瘤医院妇科 辽宁 沈阳 110042  
屈 娜 辽宁省肿瘤医院/中国医科大学肿瘤医院妇科 辽宁 沈阳 110042  
Hits: 704
Download times: 399
中文摘要:
      摘要 目的:研究卵巢癌患者血清肝素结合性表皮生长因子(HB-EGF)、胸苷激酶1(TK1)、生长分化因子15(GDF15)水平与临床病理特征和预后的关系。方法:利用酶联免疫吸附试验(ELISA)检测94例卵巢癌患者和60例健康体检志愿者的血清HB-EGF、TK1、GDF15水平。Pearson相关分析卵巢癌患者血清HB-EGF、TK1、GDF15三者的相关性。分析卵巢癌患者血清HB-EGF、TK1、GDF15水平与临床病理特征的关系。Kaplan-Meier生存分析不同血清HB-EGF、TK1、GDF15水平的卵巢癌患者的生存率差异。单因素及多因素COX回归分析影响卵巢癌患者生存预后的因素。结果:与健康对照组相比,卵巢癌组患者血清HB-EGF、TK1、GDF15水平明显较高(均P<0.05)。卵巢癌组患者血清HB-EGF与TK1、GDF15水平呈正相关,TK1与GDF15水平呈正相关(均P<0.05)。卵巢癌患者血清HB-EGF、TK1、GDF15水平与FIGO分期、分化程度有关(均P<0.05)。血清HB-EGF、TK1、GDF15高水平的卵巢癌患者3年总体生存率分别低于低水平患者(P<0.05)。血清HB-EGF、TK1、GDF15高水平、FIGO分期为Ⅲ期及低分化程度是影响卵巢癌患者预后的独立危险因素。结论:卵巢癌患者血清中HB-EGF、TK1、GDF15水平升高,三者水平与卵巢癌肿瘤FIGO分期、肿瘤分化程度有关,检测血清HB-EGF、TK1、GDF15水平有助于评估卵巢癌患者的预后。
英文摘要:
      ABSTRACT Objective: To study the levels of serum heparin-binding epidermal growth factor (HB-EGF), thymidine kinase 1 (TK1) and growth differentiation factor 15 (GDF15) of patients with ovarian cancer and their relationship with clinicopathological characteristics and prognosis. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of serum HB-EGF, TK1 and GDF15 of 94 patients with ovarian cancer and 60 health examination volunteers. Pearson correlation analysis was used to analyze the correlation between the level of serum HB-EGF, TK1 and GDF15 of patients with ovarian cancer. The relationship of serum HB-EGF, TK1 and GDF15 with the clinicopathological characteristics of patients with ovarian cancer were statistically analyzed. Kaplan-Meier survival analysis was used to analyze the levels of serum HB-EGF, TK1 and GDF15 were different from those in patients with ovarian cancer. Univariate and multivariate Cox regression analysis were used to analyze the factors affecting the survival and prognosis of patients with ovarian cancer. Results: Compared with the healthy control group, the levels of serum HB-EGF, TK1 and GDF15 of patients with ovarian cancer were significantly higher (all P<0.05). The level of serum HB-EGF of patients with ovarian cancer was positively correlated with the levels of TK1 and GDF15, and the levels of TK1 and GDF15 was positively correlated (all P<0.05). The levels of serum HB-EGF, TK1 and GDF15 of patients with ovarian cancer were related to FIGO stage and degree of differentiation (all P<0.05). The 3-year overall survival rates of patients with ovarian cancer with high level of serum HB-EGF, TK1 and GDF15 were lower than those with low level (P<0.05). High level of serum HB-EGF, TK1 and GDF15, FIGO stage III and low differentiation were independent risk factors affecting the prognosis of patients with ovarian cancer. Conclusion: The levels of serum HB-EGF, TK1 and GDF15 in patients with ovarian cancer are elevated. Their levels are related to FIGO stage and tumor differentiation. They may be new tumor markers for prognosis evaluation of ovarian cancer.
View Full Text   View/Add Comment  Download reader
Close